Clinical Research Directory
Browse clinical research sites, groups, and studies.
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
Sponsor: Stemline Therapeutics, Inc.
Summary
This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.
Official title: A Phase 1, First-in-Human Study of MEN2501, a KIF18A Inhibitor, as Monotherapy in Participants With Platinum-Resistant Ovarian Cancer
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2026-01-10
Completion Date
2028-06-02
Last Updated
2026-07-06
Healthy Volunteers
No
Conditions
Interventions
MEN2501
Oral tablet
Locations (15)
Highlands Oncology Group
Springdale, Arkansas, United States
Yale University
New Haven, Connecticut, United States
Florida Cancer Specialists & Research Institute
Sarasota, Florida, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
NEXT Virginia
Fairfax, Virginia, United States
Icon Cancer Centre
South Brisbane, Queensland, Australia
Cancer Research SA
Aberfoyle Park, Australia
Hospital Universitario Dexeus - Grupo Quironsalud
Barcelona, Spain
Clínica Universidad Navarra
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario HM Sanchinarro
Madrid, Spain
Clínica Universidad de Navarra
Pamplona, Spain
Hospital Quironsalud Madrid
Pozuelo de Alarcón, Spain